SK Pharmteco invests US$260M in new manufacturing facility in South Korea

SOUTH KOREA—SK Pharmteco, a global contract development and manufacturing organisation (CDMO), has unveiled plans to invest US$260 million to boost its production of small molecules and peptides.

 The investment will fund the construction of a cutting-edge facility in Sejong, South Korea, expected to become operational by late 2026.

This new plant will be the company’s fifth facility in South Korea, further solidifying SK Pharmteco’s presence in the country and strengthening its global manufacturing network.

The facility, which will span an impressive 135,800 square feet, will have eight production trains capable of delivering tens of metric tons of output annually.

Additionally, the facility will house advanced peptide research and development (R&D) laboratories, CGMP (current Good Manufacturing Practice) kilo labs, and a CGMP pilot plant for peptide manufacturing.

These state-of-the-art resources will allow SK Pharmteco to support both early-stage clinical trials and commercial production, offering enhanced flexibility in the production process.

As part of this ambitious expansion, the company also lays the foundation for a sixth manufacturing plant.

This strategic move is designed to allow for a rapid increase in production capacity in the future, ensuring that SK Pharmteco can respond swiftly to growing industry demand.

Commenting on the investment, Joerg Ahlgrimm, CEO of SK Pharmteco, emphasized that this expansion reflects the company’s commitment to meeting the evolving needs of the life sciences industry.

He highlighted that by investing in this new facility, the company is boosting its capacity in Asia and aligning with its global expansion strategy.

According to Ahlgrimm, this initiative reinforces SK Pharmteco’s position as a trusted partner for companies developing groundbreaking therapies, showcasing the company’s ability to adapt and remain reliable in an ever-changing industry landscape.

Yongwoo Park, SK pharmteco’s President of Small Molecule, Asia, added that the new facility represents a significant investment in the company’s future, highlighting its commitment to delivering exceptional value to customers.

Park noted that with expanded capacity and enhanced capabilities, SK Pharmteco will be able to offer faster turnaround times, increased flexibility, and superior quality in its services.

Furthermore, Park pointed out that this expansion cements the company’s reputation as a reliable partner for firms developing innovative cell and gene therapies and small molecules, facilitating the acceleration of life-changing treatments from development to commercialisation.

To support this expansion, SK Pharmteco plans to recruit over 300 new employees at the Sejong site, reinforcing its dedication to both local job creation and industry growth.

 The company’s investment highlights its commitment to meeting the rising global demand for high-quality peptides and small molecules, essential components of many modern therapies.

The life sciences industry is currently experiencing rapid growth, driven by technological advancements and the increasing demand for innovative treatments.

However, challenges such as limited manufacturing capacity and complex regulatory frameworks continue to hinder the global supply chain for these therapies.

SK Pharmteco’s new facility seeks to address these challenges by offering a scalable and dependable solution for producing critical therapies, further solidifying its role as a key player in the industry.

Sign up to receive our email newsletters with the latest news updates and  insights from Africa and the World HERE

Newer Post

Thumbnail for SK Pharmteco invests US$260M in new manufacturing facility in South Korea

Bavarian Nordic secures US$63M contract for JYNNEOS Vaccine

Older Post

Thumbnail for SK Pharmteco invests US$260M in new manufacturing facility in South Korea

Johnson & Johnson seeks FDA Approval for promising multiple myeloma therapy

Be the first to leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.